Circulating plasma MiR-141 is a novel biomarker for metastatic colon cancer and predicts poor prognosis.
Circulating plasma MiR-141 is a novel biomarker for metastatic colon cancer and predicts poor prognosis.
复制标题
DOI：
10.1371/journal.pone.0017745
复制
发表时间：
2011-03-17
期刊：
影响因子：
3.7
通讯作者：
Zhang W
中科院分区：
文献类型：
--
作者：
Cheng H;Zhang L;Cogdell DE;Zheng H;Schetter AJ;Nykter M;Harris CC;Chen K;Hamilton SR;Zhang W
结直肠癌（CRC）仍然是世界范围内的主要癌症类型和癌症相关死亡之一。敏感的、非侵入性的生物标志物可以促进疾病检测、分期和治疗结果的预测，这对于提高生存率和帮助确定CRC的优化治疗是非常需要的。小的非编码RNA，microRNA（miRNAs），最近被鉴定为包括癌症在内的各种疾病的关键调节因子，并且可能代表一类新的癌症生物标志物。本研究的目的是鉴定和验证人血浆中的循环microRNA，以用作结肠癌的生物标志物。通过使用定量逆转录-聚合酶链反应，我们发现循环miR-141与102份血浆样本队列中的IV期结肠癌显著相关。采用受试者工作特征（ROC）分析评价候选血浆microRNA标志物的敏感性和特异性。我们观察到，miR-141和癌胚抗原（CEA）（一种广泛使用的CRC标记物）的组合进一步提高了检测的准确性。这些结果在中国天津采集的156份血浆样本的独立队列中得到验证。此外，我们的分析表明，高水平的血浆miR-141预测两个队列中的生存率较差，并且miR-141是晚期结肠癌的独立预后因素。我们认为，血浆miR-141可能是一种新的生物标志物，在检测结肠癌远处转移中补充CEA，血浆中高水平的miR-141与预后不良相关。
Colorectal cancer (CRC) remains one of the major cancer types and cancer related death worldwide. Sensitive, non-invasive biomarkers that can facilitate disease detection, staging and prediction of therapeutic outcome are highly desirable to improve survival rate and help to determine optimized treatment for CRC. The small non-coding RNAs, microRNAs (miRNAs), have recently been identified as critical regulators for various diseases including cancer and may represent a novel class of cancer biomarkers. The purpose of this study was to identify and validate circulating microRNAs in human plasma for use as such biomarkers in colon cancer. By using quantitative reverse transcription-polymerase chain reaction, we found that circulating miR-141 was significantly associated with stage IV colon cancer in a cohort of 102 plasma samples. Receiver operating characteristic (ROC) analysis was used to evaluate the sensitivity and specificity of candidate plasma microRNA markers. We observed that combination of miR-141 and carcinoembryonic antigen (CEA), a widely used marker for CRC, further improved the accuracy of detection. These findings were validated in an independent cohort of 156 plasma samples collected at Tianjin, China. Furthermore, our analysis showed that high levels of plasma miR-141 predicted poor survival in both cohorts and that miR-141 was an independent prognostic factor for advanced colon cancer. We propose that plasma miR-141 may represent a novel biomarker that complements CEA in detecting colon cancer with distant metastasis and that high levels of miR-141 in plasma were associated with poor prognosis.
登录
查看更多内容
影响因子：
2
作者：
Akao, Yukihiro;Nakagawa, Yoshihito;Naoe, Tomoki
通讯作者：
Naoe, Tomoki
影响因子：
120.7
作者：
Schetter, Aaron J.;Leung, Suet Yi;Harris, Curtis C.
通讯作者：
Harris, Curtis C.
影响因子：
254.7
作者：
Parkin, DM;Bray, F;Pisani, P
通讯作者：
Pisani, P
影响因子：
2.2
作者：
Fabbri, Muller;Croce, Carlo M.;Calin, George A.
通讯作者：
Calin, George A.
影响因子：
9.3
作者：
Chim, Stephen S. C.;Shing, Tristan K. F.;Lo, Y. M. Dennis
通讯作者：
Lo, Y. M. Dennis